approval
saveOPDIVO (NIVOLUMAB) — FDA approval
community read0 votes
Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- phase 1 initiationVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)Apr 30, 2026 · 155d ago
- phase 1 2 completionChiba Cancer Center — nivolumab (Phase I/II Trial Completion)Apr 30, 2026 · 155d ago
- phase 2 completionPt.Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences Rohtak — nivolumab (Phase II Trial Completion)Apr 27, 2026 · 158d ago
- approvalOPDIVO (NIVOLUMAB) — FDA approvalMar 20, 2026 · 196d ago
- approvalOPDIVO (NIVOLUMAB) — FDA approvalJul 1, 2025 · 458d ago
- approvalOPDIVO (NIVOLUMAB) — FDA approvalMay 23, 2025 · 497d ago
- approvalOPDIVO (NIVOLUMAB) — FDA approvalApr 11, 2025 · 539d ago
- approvalOPDIVO (NIVOLUMAB) — FDA approvalApr 8, 2025 · 542d ago
same company · ±60 days · 1
🐶 often sniffed alongside
top 8- drugOPDIVO356 co-mentions · 92 sources
- drugOPDIVO QVANTIG356 co-mentions · 92 sources
- tagApproval352 co-mentions · 88 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO166 co-mentions · 83 sources
- company$BMYBRISTOL MYERS SQUIBB CO166 co-mentions · 83 sources
- companyBristol-Myers Squibb Co12 co-mentions · 6 sources
- tagOncology10 co-mentions · 3 sources
- drug(hyaluronidase (recombinant, human) + nivolumab)10 co-mentions · 5 sources
comments(0)
5-min edit window · permanent after that